pentavalent pathogen-specific T cells

Pentavalent pathogen-specific T cells (penta-STs), also known as Penta-STs-001, are donor-derived, non-genetically engineered, multi-pathogen-specific T lymphocytes developed by the George Papanicolaou Hospital in collaboration with the University Hospital of Patras. This cell therapy is designed to simultaneously target five major opportunistic pathogens that cause severe morbidity and mortality in immunocompromised patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT): cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus (BKV), adenovirus (AdV), and the fungus Aspergillus fumigatus (AF). The therapeutic T cells are manufactured by pulsing peripheral blood mononuclear cells (PBMCs) from healthy, immunocompetent donors with overlapping peptide libraries spanning immunogenic antigens of the five target pathogens (including CMV pp65/IE1, EBV LMP2/EBNA1/BZLF1, BKV Large T/VP1, AdV Hexon/Penton, and AF Gel1/SHMT/Crf1) and expanding them in vitro in the presence of IL-4 and IL-7. Penta-STs are administered intravenously to restore protective cellular immunity and treat refractory or drug-resistant opportunistic infections post-transplant.

Other names

multipathogen-specific T-lymphocytespenta-STspentavalent-specific T cellspentavalent-specific T-cells